Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Biobeat Secures $50 Million Series B Financing to Advance Commercialization of its Patch-worn, Cuff-less 24-hour Ambulatory Blood Pressure Monitor Biobeat Technologies, Ltd., developer of the first ...
*The main analyses of ambulatory BP endpoints include patients with valid ambulatory blood pressure monitoring at both baseline and Week 12, without imputation of missing data. The Phase III Bax24 ...
Please provide your email address to receive an email when new articles are posted on . Baxdrostat reduced 24-hour blood pressure in patients with resistant hypertension already on maximally tolerated ...
NEW HOPE, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to ...
A new system that uses dehydrated alcohol to deactivate certain nerves surrounding the kidneys' arteries in order to control high blood pressure met its primary endpoint—lowering blood pressure at ...
A new system that uses dehydrated alcohol to deactivate certain nerves surrounding the kidneys' arteries in order to control high blood pressure met its primary endpoint—lowering blood pressure at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results